Press Releases

Press Releases

    Date Title View
    12/27/17
    Summary ToggleHorizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis
    PDF Version
    12/18/17
    Summary ToggleHorizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference
    PDF Version
    12/05/17
    Summary ToggleHorizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PDF Version
    11/30/17
    Summary ToggleHorizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
    PDF Version
    11/30/17
    Summary ToggleHorizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
    PDF Version
    11/10/17
    Summary ToggleHorizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
    PDF Version
    11/07/17
    Summary ToggleHorizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PDF Version
    11/06/17
    Summary ToggleHorizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
    PDF Version
    11/06/17
    Summary ToggleHorizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
    11/04/17
    Summary ToggleHorizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
    PDF Version
    Displaying 1 - 10 of 51 results